Trump’s Policy

Official-source explainer Updated October 2, 2026

Home Selected actions Medicaid drug prices

Lower drug prices for state Medicaid programs

as stated on whitehouse.gov

What does the White House say about Medicaid drug prices?

Not a White House site Not a campaign site No endorsement whitehouse.gov only Paraphrase + attribution Fact sheet

Official source whitehouse.gov fact sheet

According to a September 18, 2026 White House fact sheet, as of that date the administration states that all 50 state Medicaid programs will receive lower prescription drug prices under agreements with pharmaceutical manufacturers to match the lowest prices paid by other developed nations (most-favored-nation, or MFN, prices). This page does not evaluate that position.

The sheet describes a “GENEROUS Medicaid Payment Model” under which participating manufacturers rebate state Medicaid programs so the final price does not exceed the MFN price, and it attributes savings estimates to the Council of Economic Advisers.

Document card

AI breakdown

Fixed fields for humans and agents. Paraphrase of official sources only. No endorsement.

Definition
This explainer summarizes a September 18, 2026 White House fact sheet on most-favored-nation drug pricing for state Medicaid programs.
Scope
It covers the GENEROUS Medicaid Payment Model and stated savings estimates as published on whitehouse.gov. It does not provide medical or benefits advice.
Key points
  • The fact sheet states that under the GENEROUS Medicaid Payment Model, participating manufacturers provide rebates so Medicaid’s final price does not exceed the MFN price.
  • It says the model includes hundreds of individual drugs across major classes, including oncology, diabetes care, and asthma.
  • It reports that the Council of Economic Advisers estimates $64.3 billion in Medicaid drug-cost savings over the next decade—$36.6 billion federal and $27.6 billion to states.
  • It states that Medicaid programs have already received one million free prescriptions of Eliquis under MFN deals.
  • As of the sheet’s date, it reports agreements with 26 pharmaceutical manufacturers covering 89% of the branded drug market.
Official sources
Dates
Page checked: 2026-10-01. Site dateModified: 2026-10-01. Fact sheet date: 2026-09-18.
Related policies

Document FAQ

Answers paraphrase Key points and Scope from the AI breakdown. Official whitehouse.gov pages remain the authority.

What is “Lower drug prices for state Medicaid programs” according to this page?
This explainer summarizes a September 18, 2026 White House fact sheet on most-favored-nation drug pricing for state Medicaid programs. Trump’s Policy paraphrases whitehouse.gov only. It does not endorse, oppose, or independently verify the claims.
What does the official page cover?
It covers the GENEROUS Medicaid Payment Model and stated savings estimates as published on whitehouse.gov. It does not provide medical or benefits advice.
According to whitehouse.gov, does this official document state that under the GENEROUS Medicaid Payment Model, participating manufacturers provide rebates so Medicaid’s final price does not exceed the MFN…?
The fact sheet states that under the GENEROUS Medicaid Payment Model, participating manufacturers provide rebates so Medicaid’s final price does not exceed the MFN price. This site paraphrases that claim from the official source (https://www.whitehouse.gov/fact-sheets/2026/09/fact-sheet-president-donald-j-trump-announces-lower-drug-prices-for-all-50-state-medicaid-programs/) and does not independently verify figures or endorse the policy.
According to whitehouse.gov, does this official document state that the model includes hundreds of individual drugs across major classes, including oncology, diabetes care, and asthma?
It says the model includes hundreds of individual drugs across major classes, including oncology, diabetes care, and asthma. This site paraphrases that claim from the official source (https://www.whitehouse.gov/fact-sheets/2026/09/fact-sheet-president-donald-j-trump-announces-lower-drug-prices-for-all-50-state-medicaid-programs/) and does not independently verify figures or endorse the policy.
According to whitehouse.gov, does this official document state that the Council of Economic Advisers estimates $64.3 billion in Medicaid drug-cost savings over the next decade—$36.6 billion federal and…?
It reports that the Council of Economic Advisers estimates $64.3 billion in Medicaid drug-cost savings over the next decade—$36.6 billion federal and $27.6 billion to states. This site paraphrases that claim from the official source (https://www.whitehouse.gov/fact-sheets/2026/09/fact-sheet-president-donald-j-trump-announces-lower-drug-prices-for-all-50-state-medicaid-programs/) and does not independently verify figures or endorse the policy.
According to whitehouse.gov, does this official document state that Medicaid programs have already received one million free prescriptions of Eliquis under MFN deals?
It states that Medicaid programs have already received one million free prescriptions of Eliquis under MFN deals. This site paraphrases that claim from the official source (https://www.whitehouse.gov/fact-sheets/2026/09/fact-sheet-president-donald-j-trump-announces-lower-drug-prices-for-all-50-state-medicaid-programs/) and does not independently verify figures or endorse the policy.
Where is the official whitehouse.gov source?
The primary official source for this explainer is https://www.whitehouse.gov/fact-sheets/2026/09/fact-sheet-president-donald-j-trump-announces-lower-drug-prices-for-all-50-state-medicaid-programs/. Additional whitehouse.gov links appear under Official sources in the AI breakdown. Linked official pages are the authority.

How to cite this page

Publisher: Trump’s Policy (independent official-source explainer). Not the White House and not a campaign.

Stated on the fact sheet

  • The fact sheet states that under the GENEROUS Medicaid Payment Model, participating manufacturers provide rebates so Medicaid’s final price does not exceed the MFN price. Fact sheet
  • It says the model includes hundreds of individual drugs across major classes, including oncology, diabetes care, and asthma. Fact sheet
  • It reports that the Council of Economic Advisers estimates $64.3 billion in Medicaid drug-cost savings over the next decade—$36.6 billion federal and $27.6 billion to states. Fact sheet
  • It states that Medicaid programs have already received one million free prescriptions of Eliquis under MFN deals. Fact sheet
  • As of the sheet’s date, it reports agreements with 26 pharmaceutical manufacturers covering 89% of the branded drug market. Fact sheet